Clinical Value of New Staging Systems for Multiple Myeloma.
- Author:
Jung Hye CHOI
1
;
Jae Hoon YOON
;
Seong Kyu YANG
Author Information
1. Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. jhcmd@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Southwest Oncology Group staging system;
International Staging System;
Multiple myeloma
- MeSH:
Female;
Humans;
Multiple Myeloma*;
Retrospective Studies
- From:Cancer Research and Treatment
2007;39(4):171-174
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. MATERIALS AND METHODS: Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36~87)) with available baseline values of albumin and beta2-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. RESULTS: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). CONCLUSION: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients.
